Halozyme Therapeutics Inc. added Eli Lilly and Co. to the roster of companies angling to develop products incorporating its Enhanze delivery platform, a potential aid in the dispersion and absorption of its injectables.
A year and a half after landing a $23.5 million series A financing, Navitor Pharmaceuticals Inc. has attracted new investors to a $33 million series B round intended to help it identify a lead candidate in a pipeline of candidates capable of modulating the mammalian target of rapamycin complex 1 pathway and carrying it into the clinic by early 2018.
Astrazeneca plc is buying 55 percent of privately held Acerta Pharma LLC, the developer of acalabrutinib, a phase III oral small-molecule Bruton's tyrosine kinase (BTK) inhibitor that it expects to transform the treatment of B-cell malignancies.
Shares of Array Biopharma Inc. (NASDAQ:ARRY) climbed 20.6 percent to $4.62 on Wednesday following news that its MEK inhibitor, binimetinib, improved progression-free survival (PFS) for patients with advanced NRAS-mutant melanoma compared to chemotherapy during the phase III Nemo study.
Kallyope Inc., a New York-based biotech company focused on developing a platform to influence the brain via the gut, has secured its first investment, a $44 million series A financing to explore the untapped therapeutic and nutritional potential of the bidirectional communication channel. From its lab, overlooking the Empire State Building, it expects to develop its own therapeutic programs in parallel with a platform for translating gut-brain biology into a range of new therapeutic and nutritional programs. But it is "not interested in therapeutics that are just incremental," CEO Nancy Thornberry, a veteran of Merck & Co. Inc., told BioWorld Today.
Members of the FDA's Pulmonary-Allergy Drugs Advisory Committee (adcom) voiced majority support on Wednesday for the approval of Teva Pharmaceutical Industries Ltd.'s Cinqair (reslizumab) injection for adults with asthma, though they stood firmly against potential use of the drug in children, 12 to 17.
ORLANDO, Fla. – New research being presented at the American Society of Hematology (ASH) meeting is adding to growing evidence that experimental gene therapies may improve the health of people with inherited bleeding and immune disorders, as well as some forms of blood cancer, but progress is not as even as investors would like.
ORLANDO, Fla. – Treating previously untreated older patients with chronic lymphocytic leukemia (CLL) with Imbruvica (ibrutinib) proved superior to standard of care treatment with the chemotherapy chlorambucil, according to new phase III data presented at the American Society of Hematology meeting and simultaneously published online in The New England Journal of Medicine.
True North Therapeutics Inc. raised $40 million in series C equity funding to advance development of its lead complement inhibitor, TNT009, through potential registration-enabling studies for cold agglutinin disease (CAD), while also advancing other complement inhibitors in its pipeline.
Kite Pharma Inc. is kicking off its ZUMA-3 study, the third in what's soon to be a quartet of pivotal studies aimed at supporting regulatory approval of KTE-C19, its anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and lead candidate.
